Aerosolized recombinant interleukin-2 (RIL-2) as treatment of pulmonary metastases of renal cell carcinoma (PMRCC).: Survival results

被引：0
|
作者：
Esteban, Emilio
Carballido Rodriguez, Joaquin
Garcia Garcia, Antonio Luis
Jimenez Lacave, Angel
Llarena, Roberto
Garcia Giron, Carlos
Maroto Rey, Pablo
Andres Conejero, Raquel
Canelas, Amaral
Carles Galceran, Joan
机构：
[1] Univ Oviedo, Hosp Cent Asturias, Serv Oncol, E-33080 Oviedo, Spain
[2] Clin Puerta Hierro, Serv Oncol, Madrid, Spain
[3] Hosp Provincial Reina Sofia, Serv Oncol, Cordoba, Spain
[4] Univ Oviedo, Hosp Cent Asturias, Serv Oncol, E-33080 Oviedo, Spain
[5] Hosp Cruces, Serv Urol, Bilbao, Spain
[6] Hosp Gen Yague, Serv Oncol, Burgos, Spain
[7] Hosp Santa Creu & Sant Pau, Serv Oncol, E-08025 Barcelona, Spain
[8] Univ Zaragoza, Hosp Clin Lozano Blesa, Serv Oncol, Zaragoza, Spain
[9] Hosp San Bernardo, Serv Oncol, Setubal, Spain
[10] Hosp del Mar, Serv Oncol, Barcelona, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：153 / 153
页数：1
相关论文
共 50 条
  • [1] Review of inhaled recombinant interleukin-2 (rIL-2) in patients with renal cell carcinoma with pulmonary metastases.
    Michelson, G
    Esteban, E
    Garcia-Giron, C
    Jimenez-Lacave, A
    Canelas, A
    Maroto, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 441S - 441S
  • [2] Observational study in patients with pulmonary metastases of renal cell carcinoma receiving inhaled recombinant interleukin-2 (rIL-2).
    García, A. G., Sr.
    Esteban, E.
    Giron, C. G.
    Maroto, P.
    Andres, R.
    Canelas, A.
    Caballido, J.
    Carles, J.
    Espinosa, E.
    Lacave, A. J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 242S - 242S
  • [3] PULMONARY AND SYSTEMIC EFFECTS OF INHALATION-THERAPY WITH RECOMBINANT INTERLEUKIN-2 (RIL-2)
    HAMM, H
    BRUGGEMANN, M
    KIRCHNER, H
    POLIWODA, H
    FABEL, H
    ATZPODIEN, J
    [J]. AMERICAN REVIEW OF RESPIRATORY DISEASE, 1993, 147 (04): : A315 - A315
  • [4] RECONSTITUTION OF RECOMBINANT INTERLEUKIN-2 (RIL-2) - A COMPARATIVE-STUDY OF VARIOUS RIL-2 MUTEINS
    VLASVELD, LT
    BEIJNEN, JH
    SEIN, JJ
    RANKIN, EM
    MELIEF, CJM
    HEKMAN, A
    [J]. EUROPEAN JOURNAL OF CANCER, 1993, 29A (14) : 1977 - 1979
  • [5] Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma - Results of a multicenter SCAPP1 trial
    Tourani, JM
    Lucas, V
    Mayeur, D
    Dufour, B
    DiPalma, M
    Boaziz, C
    Grise, P
    Varette, C
    Pavlovitch, JM
    PujadeLauraine, E
    Larregain, D
    Ecstein, E
    Untereiner, M
    Vuillemin, E
    Merran, S
    Andrieu, JM
    [J]. ANNALS OF ONCOLOGY, 1996, 7 (05) : 525 - 528
  • [6] ALLOGENEIC LYMPHOKINE ACTIVATED KILLER (LAK) CELLS AND RECOMBINANT INTERLEUKIN-2 (RIL-2) REDUCE ESTABLISHED PULMONARY METASTASES
    SHILONI, E
    MULE, JJ
    SCHWARZ, S
    ROSENBERG, SA
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 362 - 362
  • [7] SURVIVAL AFTER TREATMENT OF ADVANCED RENAL-CELL CARCINOMA (RCC) WITH HIGH-DOSE INTERLEUKIN-2 (RIL-2) OR VINBLASTINE (VLB)
    SORIO, R
    GALLIGIONI, E
    CRIVELLARI, D
    TALAMINI, R
    MONFARDINI, S
    [J]. ANNALS OF ONCOLOGY, 1995, 6 (03) : 306 - 307
  • [8] HYPERBILIRUBINEMIA IN PATIENTS TREATED WITH RECOMBINANT HUMAN INTERLEUKIN-2 (RIL-2)
    PUNT, CJA
    HENZENLOGMANS, SC
    BOLHUIS, RLH
    STOTER, G
    [J]. BRITISH JOURNAL OF CANCER, 1990, 61 (03) : 491 - 491
  • [9] CONTINUOUS INFUSION RECOMBINANT INTERLEUKIN-2(RIL-2) IN ADOPTIVE CELLULAR THERAPY OF RENAL-CARCINOMA AND OTHER MALIGNANCIES
    WEST, WH
    [J]. CANCER TREATMENT REVIEWS, 1989, 16 : 83 - 89
  • [10] PHARMACOKINETIC ALTERATION IN RATS OF RECOMBINANT INTERLEUKIN-2 (RIL-2) BY IMMUNOCOMPLEXING WITH A MONOCLONAL-ANTIBODY AGAINST RIL-2
    SATO, J
    HAMAGUCHI, N
    DOKEN, K
    IWASA, S
    OGAWA, Y
    TOGUCHI, H
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 1994, 17 (04) : 535 - 538
12345